SANGAMO THERAPEUTICS, INC - Common Stock (SGMO)

Q2 2023 13F Holders as of 30 Jun 2023

Type / Class
Equity / Common Stock
Shares outstanding
294,683,714
Total 13F shares
105,778,869
Share change
-6,209,528
Total reported value
$137,125,383
Put/Call ratio
76%
Price per share
$1.30
Number of holders
149
Value change
-$10,782,201
Number of buys
68
Number of sells
91

Institutional Holders of SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) as of Q2 2023

As of 30 Jun 2023, SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) was held by 149 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 105,778,869 shares. The largest 10 holders included WASATCH ADVISORS LP, BlackRock Inc., VANGUARD GROUP INC, Rokos Capital Management LLP, CITADEL ADVISORS LLC, CREDIT SUISSE AG/, RENAISSANCE TECHNOLOGIES LLC, GEODE CAPITAL MANAGEMENT, LLC, ACADIAN ASSET MANAGEMENT LLC, and STATE STREET CORP. This page lists 149 institutional shareholders reporting positions in this security for the Q2 2023 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.